Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

HONG KONG And GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ — Sirnaomics Ltd. (The “Company”Stock Code: 2257.HK, and together with its subsidiaries the “Group” or “sirnaomics”), a biopharmaceutical leader in the discovery and development of advanced RNAi therapeutics, announced today that Dr. Patrick LuChairman of the Board, Executive Director, President and Chief Executive Officer and Dr. Richard W. Welch, Vice President of Chemistry, Manufacturing, and Controls Processes (CMC), will be keynote speakers during the 4th Annual RNAi-Based Therapeutic Summit. The conference that will be held in Boston, MAMarch 21-23, 2023, aims to bring together prominent drug developers and academics, ultimately leading to the successful delivery of siRNA into extrahepatic tissues.

dr Lu will showcase the company’s proprietary polypeptide nanoparticle (PNP) technology for RNAi cancer therapeutics, demonstrating dual-targeted drug design using either a local formulation or a systemic formulation to treat various cancers, such as: B. Non-melanoma skin cancer, cholangiocarcinoma, pancreatic cancer and metastatic melanoma. The positive clinical results from multiple Phase II studies for the treatment of squamous cell carcinoma in situ and basal cell carcinoma of STP705 allow the company to move into late-stage clinical development. Exploiting the targeting property of PNP with siRNA drug payloads, specifically against activated endothelial cells, the company conducted a Phase I basket study of STP707 for the treatment of multiple solid cancers. The starting dose escalation study has demonstrated an excellent safety profile with obvious therapeutic benefit to patients.

DR patrick lus presentation details

Presentation title: Key Clinical Trial Results for Novel RNAi Anticancer Therapeutics.

Time date: 9:00 a.m. EST on Wednesday, March 22, 2023.

The story goes on

Presentation details:

• Advantage of delivery of polypeptide nanoparticles for siRNA cancer therapeutics.

• Local formulation of STP705 for the treatment of non-melanoma skin cancer

• STP707 systemic formulation for the treatment of liver and pancreatic cancer

DR Richard W. Welchs presentation details

Presentation title: Development of robust processes to enable scaling of large-scale production for the clinic – insights from the development and scaling of novel platforms

Time date: 3:30 p.m. EST on ThursdayMarch 23, 2023.

Presentation details:

• Overview of the early phase of clinical development of one of the company’s core platforms, including not only the challenges in the early phase and the translation from concept to clinical, but also indications of the challenges in commercialization

• Examine how the use of platform technologies can streamline development and provide time and resource savings.

• An overview of how recent changes in the global supply chain and global regulatory and legal frameworks continue to pose challenges in translating concepts into clinical material.

About the 4th RNAi-Based Therapeutics Summit

The 4th Summit on RNAi-based Therapeutics returns Boston To welcome more than 90 technical and strategic experts dedicated to early discovery, preclinical, clinical, supply and manufacturing activities and to foster learning and networking with pioneers in the field to bring more RNAi therapies into clinics and eventually to extrahepatic tissue. With a brand new focus day leading up to the conference evaluating next-generation delivery technologies, this summit offers full end-to-end RNAi drug development to support your own journey to realizing the full potential of siRNA.

About Sirnaomics

Sirnaomics is a preclinical and clinical stage RNA therapeutics biopharmaceutical company focused on the discovery and development of innovative medicines for indications with unmet medical needs and high market opportunity. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both areas China And The United States, and also the first company to achieve positive Phase II clinical results in oncology for an RNAi therapeutic for its lead product STP705. Learn more at www.sirnaomics.com.

View original content: https://www.prnewswire.com/apac/news-releases/sirnaomics-to-present-latest-developments-in-polypeptide-nanoparticle-platform-at-the-4th-annual-rnai-based-therapy-summit -301776278.html

SOURCE Sirnaomik